Here's a press release from 3/25/14:
Wedbush maintained an Outperform rating on Endocyte (NASDAQ: ECYT) and raised its price target to $65.00 (from $27.00). The stock was also added to Wedbush's Best Ideas List.
Analyst Gregory R. Wade said, "We believe positive PFS and OS data in lung cancer de-risk ECYT's small molecule drug conjugate technology platform and suggest to us a broader opportunity for VYNFINIT and ECYT’s tubulysin pipeline drug than is being valued by the Street. We expect recognition of the broad utility of ECYT’s platform technology and positive 2014 updates from PROCEED and TARGET to drive further appreciation of ECYT's shares."
As you may know by now, (and condolences to justarook), ECYT today plummeted to $6.63 on bad pIII trial news.
Let's hope that Greg Wade's remarkable powers of prognostication maintain their consistency and INSM is the stock that rockets to $65, when his target price is $7.